Gene · 8744
NIH grants1,618
NIH grants whose papers are about the gene, through NIH's grant-paper links.
21 to 40 of 1,618
Download this page as JSON| Grant | Title | TNFSF9 papers | Newest fiscal year |
|---|---|---|---|
| P30CA023108 | Cancer Center Support Grant | 4 | 2025 |
| P30CA124435 | Stanford Cancer Institute | 4 | 2025 |
| R01CA266457 | Phase 1 Evaluation of Enhanced Natural Killer Cells as a Treatment Strategy in Non-Small cell Lung Cancer Patients Refractory to PD-1/PD-L1 Immune Checkpoint Inhibitors | 4 | 2025 |
| U54GM104942 | West Virginia Clinical and Translational Science Institute: A Statewide Organization Building Research Excellence and Engaging Communities to Improve Health | 4 | 2025 |
| ZIABC010975 | Vaccine and radiation for the therapy of human cancers | 4 | 2025 |
| P30AI045008 | Penn Center for AIDS Research | 3 | 2025 |
| P30CA010815 | Consolidated Basic Cancer Research Program | 3 | 2025 |
| P30CA014520 | UW Comprehensive Cancer Center Support | 3 | 2025 |
| P30CA016042 | Cancer Center Support Grant | 3 | 2025 |
| P30CA046934 | University of Colorado Cancer Center Support Grant | 3 | 2025 |
| P30CA060553 | The Robert H. Lurie Comprehensive Cancer Center | 3 | 2025 |
| P30CA093373 | Cancer Center Support Grant P30 | 3 | 2025 |
| P30ES013508 | Center of Excellence in Environmental Toxicology | 3 | 2025 |
| P50CA097190 | Head and Neck Cancer SPORE | 3 | 2025 |
| P50CA121974 | Yale SPORE in Skin Cancer | 3 | 2025 |
| P50CA127001 | SPORE in Brain Cancer | 3 | 2025 |
| R01CA114536 | Novel synthetic receptors with improved antigen specificity and specificity for cancer therapy | 3 | 2025 |
| R01NS097851 | IDO1 and Immunotolerance in Glioblastoma | 3 | 2025 |
| UL1TR001863 | Yale Clinical and Translational Science Award | 3 | 2025 |
| ZIAAG000770 | Immunology of aging and immunotherapy of aging-associated diseases | 3 | 2025 |
Source NIH's project filesgene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/8744/grants?page=2